Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.40 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6536824 | 0.88 | PSMB1 (0.47) | PSMB1L3MBTL1POLBNPSR1NPC1 | |
| SCHEMBL9752595 | 0.86 | L3MBTL1 (0.55) | PSMB1L3MBTL1POLBNPSR1NPC1 | |
| SCHEMBL11611166 | 0.84 | PSMB1 (0.45) | PSMB1L3MBTL1POLBNPSR1NPC1 | |
| SCHEMBL9394796 | 0.82 | L3MBTL1 (0.51) | PSMB1L3MBTL1POLBNPSR1NPC1 | |
| SCHEMBL8600961 | 0.82 | — | — | |
| SCHEMBL9752675 | 0.82 | L3MBTL1 (0.51) | PSMB1L3MBTL1POLBNPSR1NPC1 | |
| SCHEMBL27088868 | 0.81 | PSMB1 (0.47) | PSMB1L3MBTL1POLBNPSR1NPC1 | |
| SCHEMBL9752719 | 0.80 | L3MBTL1 (0.50) | PSMB1L3MBTL1POLBNPSR1NPC1 | |
| SCHEMBL9752728 | 0.80 | L3MBTL1 (0.50) | PSMB1L3MBTL1POLBNPSR1NPC1 | |
| SCHEMBL9752571 | 0.80 | L3MBTL1 (0.50) | PSMB1L3MBTL1POLBNPSR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1991009848-A1 | PYRIDINONES USEFUL AS ANTIATHEROSCLEROTIC AGENTS | THE UPJOHN COMPANY (US) | 1991-07-11 | — | — | WO | claimed |
| CN-122070282-A | Pyrazole-1-carboxamides as RIP1 kinase inhibitors | 比西切姆有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4320132-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117083279-A | Oxazepine compounds and their use in the treatment of cancer | 基因泰克公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-112279852-B | Triazolo-pyrimidine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| WO-2022216762-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| CN-111635408-B | Triazolo-pyrimidine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3820474-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | Nikang Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| CN-112423758-A | Adenosine receptor binding compounds | 尼康治疗公司 | 2021-02-26 | — | — | CN | disclosed |
| US-6639093-B2 | Reacting benzyl chloride with hydroxybenzoic acid | BAYER AKTIENGESELLSCHAFT (DE) | 2003-10-28 | — | — | US | disclosed |
| WO-2003047516-A2 | PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
| US-20030053964-A1 | Process for the preparation of hydroxybenzoic benzyl esters | BAYER AKTIENGESELLSCHAFT (DE) | 2003-03-20 | — | — | US | disclosed |
| EP-1249443-A2 | Process for the production of hydroxybenzoic acid benzyl esters | BAYER AG (DE) | 2002-10-16 | — | — | EP | disclosed |
| US-5935977-A | PHOSPHODIESTERASE IV INHIBITORS, TUMOR NECROSIS FACTOR-ALPHA PRODUCTION INHIBITORS; TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES | SS PHARMACEUTICAL CO., LTD. (JP) | 1999-08-10 | — | — | US | disclosed |
| CN-1206407-A | Substituted vinylpyridine derivatives and medicaments containing them | SS PHARMACEUTICAL CO (JP) | 1999-01-27 | — | — | CN | disclosed |
| EP-0882714-A1 | SUBSTITUTED VINYLPYRIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SS Pharmaceutical Co., Ltd. (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-4588816-A | Preparation of (2-(6-substituted)-pyridinyloxy)alkanols from 2-(6-substituted)pyridinols and organic carbonates | THE DOW CHEMICAL COMPANY (US) | 1986-05-13 | — | — | US | disclosed |
| US-4568677-A | CONTROLLED COOLING | PFIZER INC. (US) | 1986-02-04 | — | — | US | disclosed |
| EP-0132375-A2 | Dihydropyridine anti-ischaemic and antihypertensive agents | Pfizer Limited (GB) | 1985-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030053964-A1 | Process for the preparation of hydroxybenzoic benzyl esters | HAAO, HPD, HACL2 | PSMB1 868/4885L3MBTL1 2479/4885POLB 504/4885 |
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | OXA1L, GRIK4, GRIK5 | PSMB1 4387/4885L3MBTL1 3131/4885POLB 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.